Lung cancer
GtoPdb Disease Summaries
This section gives an overview of the disease, and where available shows the following:
- Synonyms: Shows known synonyms for the disease.
- Description: Gives a basic description/definition of the disease.
- Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
- Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
- Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.
More information can be found in the help pages.
✖| Disease ID: | 567 | |
| Name: | Lung cancer | |
| Associated with: | 13 targets | |
Targets
GtoPdb Disease Summaries - Targets
Click on the target name to link to its detailed view page
Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.
If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page
Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.
More information can be found in the help pages.
✖| ADGRB1 | |
| Role: | Mutations in ADGRB1 are associated with squamous cell carcinoma of the lung |
| References: | 4 |
| Mutations: | ADGRB1 is associated with 3 mutation. Click here for details  |
| ADGRB2 | |
| Role: | Mutations in ADGRB2 are associated with squamous cell carcinoma of the lung and other forms of lung cancer |
| References: | 4 |
| Mutations: | ADGRB2 is associated with 3 mutation. Click here for details |
| ADGRB3 | |
| Role: | Mutations in BAI3 are associated with lung adenocarcinoma, squamous cell carcimoma and small cell carcinoma |
| References: | 4 |
| Mutations: | ADGRB3 is associated with 19 mutation. Click here for details |
| FZD7 | |
| References: | 5,8 |
| FZD8 | |
| References: | 1,10 |
| PKR1 | |
| References: | 6 |
| Mutations: | PKR1 is associated with 7 mutation. Click here for details |
| Retinoic acid receptor-β | |
| Role: | Non-small-cell lung cancer is associated with RARb loss-of expression. |
| References: | 2,7,11 |
| Caspase 8 | |
| Role: | A deletion allele in CASP8 is associated with reduced risk of lung cancer |
| Mutations: | Caspase 8 is associated with 1 mutation. Click here for details |
| epidermal growth factor receptor | |
| Role: | Mutations in EGFR are associated with non-small cell lung cancer and adenocarcinoma of the lung. |
| B-Raf proto-oncogene, serine/threonine kinase | |
| Role: | Mutations in BRAF are associated with lung adenocarcinoma |
| erb-b2 receptor tyrosine kinase 2 | |
| Role: | Mutations in ERBB2 are associated with lung adenocarcinoma |
| regulator of G-protein signaling 12 | |
| Comments: | Non-small cell lung cancer |
| References: | 3 |
| KRAS |
Ligands
GtoPdb Disease Summaries - Ligands
Click ligand name to view ligand summary page
- Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
- Immuno: Immuno icon indicates the ligand is immuno-relevant
Click the arrow in the final column to expand comments
- Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
- Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
- Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.
More information can be found in the help pages.
✖No ligand related data available for Lung cancer
References
1. Bravo DT, Yang YL, Kuchenbecker K, Hung MS, Xu Z, Jablons DM, You L. (2013) Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC Cancer, 13: 316. [PMID:23815780]
2. Castillo L, Milano G, Santini J, Demard F, Pierrefite V. (1997) Analysis of retinoic acid receptor beta expression in normal and malignant laryngeal mucosa by a sensitive and routine applicable reverse transcription-polymerase chain reaction enzyme-linked immunosorbent assay method. Clin Cancer Res, 3 (11): 2137-42. [PMID:9815607]
3. Dai J, Gu J, Lu C, Lin J, Stewart D, Chang D, Roth JA, Wu X. (2011) Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PLoS ONE, 6 (6): e21120. [PMID:21698121]
4. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature, 466 (7308): 869-73. [PMID:20668451]
5. King TD, Zhang W, Suto MJ, Li Y. (2012) Frizzled7 as an emerging target for cancer therapy. Cell Signal, 24 (4): 846-51. [PMID:22182510]
6. O'Hayre M, Vázquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS. (2013) The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer, 13 (6): 412-24. [PMID:23640210]
7. Picard E, Seguin C, Monhoven N, Rochette-Egly C, Siat J, Borrelly J, Martinet Y, Martinet N, Vignaud JM. (1999) Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J Natl Cancer Inst, 91 (12): 1059-66. [PMID:10379969]
8. Sagara N, Toda G, Hirai M, Terada M, Katoh M. (1998) Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7. Biochem Biophys Res Commun, 252 (1): 117-22. [PMID:9813155]
9. Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, Guo Y, Yang M, Zhang X, Zhang Q et al.. (2007) A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet, 39 (5): 605-13. [PMID:17450141]
10. Wang HQ, Xu ML, Ma J, Zhang Y, Xie CH. (2012) Frizzled-8 as a putative therapeutic target in human lung cancer. Biochem Biophys Res Commun, 417 (1): 62-6. [PMID:22138402]
11. Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong WK, Lotan R. (1997) Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst, 89 (9): 624-9. [PMID:9150186]
